Rank Protein Immunolabeling during Bone-Implant Interface Healing Process by Ávila Souza, Francisley et al.
Hindawi Publishing Corporation
International Journal of Dentistry





Francisley ´ AvilaSouza,1 ThallitaPereiraQueiroz,1 Elo´ aR od rig uesL u viz u t o , 1
Renato SussumuNishioka,2 Idelmo RangelGarcia-JR,1
Paulo S´ ergioPerri de Carvalho,1 andRoberta Okamoto1
1Department of Surgery and General Clinical, Arac ¸atuba Dental School, Universidade Estadual Paulista, UNESP,
Rua Jos´ eB o n i f´ acio 1190, Bloco 10A, Vila Mendonc ¸a, 16015-050 Arac ¸atuba, Brazil
2Department of Dental Materials and Prothesis, S˜ ao Jos´ e dos Campos Dental School, Universidade Estadual Paulista, UNESP, Brazil
Correspondence should be addressed to Francisley ´ Avila Souza, f.avilasouza@ig.com.br
Received 24 March 2010; Revised 18 June 2010; Accepted 18 June 2010
Academic Editor: A. B. M. Rabie
Copyright © 2010 Francisley ´ Avila Souza et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The purpose of this paper was to evaluate the expression of RANK protein during bone-healing process around machined surface
implants. Twenty male Wistar rats, 90 days old, after having had a 2mm diameter and 6 mm long implant inserted in their right
tibias,wereevaluatedat7,14,21,and42daysafterhealing.Afterobtainingthehistologicalsamples,slidesweresubjectedtoRANK
immunostaining reaction. Results were quantitatively evaluated. Results. Immunolabeling analysis showed expressions of RANK
in osteoclast and osteoblast lineage cells. The statistical analysis showed an increase in the expression of RANK in osteoblasts at 7
postoperative days and a gradual decrease during the chronology of the healing process demonstrated by mild cellular activity in
the ﬁnal stage (P<. 05). Conclusion. RANK immunolabeling was observed especially in osteoclast and osteoblast cells in primary
bone during the initial periods of bone-healing/implant interface.
1.Introduction
Of the signiﬁcant advances in dentistry during the twentieth
century, unquestionably none has extended the treatment
horizons more than the successful use of osseointegrated
implants. Applying the principles of osseointegration, dental
surgeons are predictably able to replace missing teeth with
excellent long-term esthetic and functional results [1].
Br¨ anemark et al. [2] have deﬁned osseointegration
as a direct structural and functional connection between
ordinary healthy bone and the implant surface, as seen
at the level of optical microscopy, producing stability and
allowing the structure to support the masticatory forces. A
release of growth factors takes place right after an implant is
inserted, which stimulates osteoblast precursors to develop
into mature osteoblasts with consecutive production of bone
tissue [3]. The process of bone remodeling, which involves
many cellular steps and is not yet well understood, has been
considered a repetition of the osteogenic lineage response
that occurs in the fetus during the developmental phases [4].
The initial step in the bone-healing process starts with
themigrationofosteogeniccells,derivedfromthemedullary
bone layer, including undiﬀerentiated mesenchymal cells,
osteocytes, and osteoblasts, directly to a framework sup-
ported by blood a clot [5, 6]. The anabolic model is the
ﬁrst response of bone healing after implant placement in
the cortical bone, similar to the process that occurs in
fracture healing [7]. Thus, biologically, there is no evidence
of complete contact between bone and the titanium surface,
but the aspect considered is the greater or lesser amount
of connective tissue, without clinical failure or fault of the
implant [8]. In machined-surface implants, there is a larger
quantityofconjunctivetissueintheinitialstagesoftherepair
process, when compared with porous-surface implants.
Therefore, the repair process around machined-surface
implants is time-dependant [9, 10]. This occurs because2 International Journal of Dentistry
the implant surface has a smaller area of contact [11]. It
is believed that retention of the blood clot is less stable,
and consequently the migration of cells of osteoblastic
origin occurs more slowly on machined surface implants.
Therefore, the bone-interface contact in machined-surface
implants is smaller in the initial stages of the repair process
when compared with porous surface implants [9, 12].
The recent discovery of the proteins of the TNF family
members has shown their roles in bone dynamics [13–16].
From these proteins, RANK is expressed in preosteoclast
lineage cells [16], controlling bone resorption [17], and
consecutively, calcium metabolism. The function of RANK
protein is related to two other bone-matrix proteins, RANKL
(receptor activator of nuclear factor kappa B ligand) and
OPG (osteoprotegerin) [18]; the interaction among them
will modulate bone turnover.
Considering the involvement of RANK, a TNF family
memberreceptor-activatorofnuclearfactorkappaB,inbone
turnover as the main pathway to achieve bone homeostasis,
the purpose of this paper was to evaluate RANK immuno-
labeling during the bone-implant interface healing process
during diﬀerent periods of its chronology.
2.MaterialandMethods
2.1. Animals. Twenty male Wistar rats, weighing between
300 and 350g, 90 days old were maintained at a temperature
of 22 8C, in a 12-h light/12-h dark cycle, ad libitum to water
and rat food. The principles of laboratory animal care (NIH
publication 85-23, 1985) [19] and national laws on animal
use were complied with in the present study, which was
authorized by the Animal Research Ethics Committee of the
S˜ ao Paulo State University, Brazil (Protocol Number 36/05).
2.2. Surgical Procedure. The animals received general anes-
thesia with xylazine (0.03mL/100gbw/im—Dopaser Lab-
oratories Calier S.A., Barcelona, Spain) and Ketamine
(0.07mL/100gbw/im—Fort Dodge Sa´ ude Animal Ltda,
Brazil). After trichotomy and antisepsis (Polyvinylpyrroli-
done iodide; Ind´ ustria Qu´ ımica e Farmacˆ eutica Rioqu´ ımica
Ltda,Brazil)oftherighttibia,adermoperiostealincisionwas
performed in the lateral view of right tibia in order to gain
surgical access. The osteotomy was performed with a speciﬁc
drill, 2mm in diameter (with an internal hexagon 1.2mm in
diameter) (SIN—Sistema Nacional de Implants, S˜ ao Paulo
Brazil) and implant placement was performed with a digital
key 1.17 (SIN, Sistema de Implante Nacional, S˜ ao Paulo,
Brazil) which ﬁtted into the 1.2mm diameter of the internal
hexagon of the implant).
T h et i s s u ew a ss u t u r e di nd i ﬀerent plans, using polylactic
acid thread (Vycril 4.0, Ethicon, Johnson Prod., S˜ ao Jos´ ed o s
Campos, Brazil) in the deep layerand nylon in thesuperﬁcial
plane (Nylon 5.0, Mononylon, Ethicon, Johnson Prod., S˜ ao
Jos´ e dos Campos, Brazil). In addition, animals received a
singledoseof20,000UIofpenicillinGbenzathine(Fontoura
Wyeth S.A.) by intraperitoneal injection and were divided
into four groups to allow analysis of the wound healing
process at 7, 14, 21, and 42 days.
2.3. Collection of Materials. After the experimental peri-
ods, the animals were anaesthetized and infusion with
4% formaldehyde (Acros Organics, New Jersey, USA), was
performed using a Masterﬂex LS perfusion pump (Cole-
Parmer Instrument Company, Vermont Hills, IL, USA), to
remove the right tibia. The bone blocks were postﬁxed
in 4% formaldehyde, demineralized in 5% EDTA (Merck,
Darmstadt, Germany) and cryoprotected in sucrose (Merck,
Darmstadt,Germany).Afterthis,theimplantswereremoved
with the use of a 1.17 key (SIN, Sistema de Implante
Nacional, S˜ ao Paulo, Brasil) which was carefully ﬁtted into
the internal hexagon of the implant, so as not to cause injury
to the bone tissue around the implants. Therefore, they were
removed after the decalciﬁcation process, and it may also
be mentioned that in the act of inserting the implant, it
was developed especially for this study, with the dimensions
already described and with an internal hexagon 1.20mm in
diameter.
Transversal sections to the area corresponding to the
implants were cut on a cryostat (Micron Zeiss, Berlin,
Germany) to obtain 14mm thick slices, thin enough to allow
an immunohistochemical analyis, which were mounted on
previously gelatinized slides.
2.4. Immunohistochemical Processing. An anti-RANK pri-
mary antibody was used (Rabbit anti-RANK polyclonal-
Santa Cruz Biotechnology, California, USA). As a secondary
antibody, a biotinylated donkey antirabbit antibody (Jackson
Immunoresearch Laboratories, West Grove, Pennsylvania,
USA) was used. The immunohistochemical reaction was
ampliﬁed with an avidin biotin system (Kit ABC- Vectastain
Elite ABC—Peroxidase Standard, reagent A and B only—
PK6100—Vector Laboratories, Burlingame, CA, USA) and
diaminobenzidine (Sigma Aldrich, St Louis, Missouri, USA)
was used as chromogen. Immunohistochemical reactions
were controlled to evaluate the speciﬁcity of the labels
omitting the primary antibody (negative controls). The
analyses were performed without the knowledge of the
examiner that was well calibrated. Positive control was
performed in the nasal cavity of rats for the osteoclast and
in primary bone of newborn rats for the osteoblast. Negative
control was performed by omitting the primary antibody to
see the veracity of the reaction.
Hematoxylin and eosin staining was performed and used
as a reference of the cytoarchiteture of the tissue sides
of the immunohistochemistry reactions; some slides were
stained with Hematoxylin and eosin in order to receive the
cytoarchitecture orientation. Data analysis was performed in
a semiquantitative manner, with scores ranging from “−”f o r
absence of marking and “+, ++ and +++” for little, medium,
and a great deal of marking, respectively.
The transversal sections allowed visualization of the
bone tissue formed in contact with the implant. The
titanium implants were removed from the samples after
the demineralization process was complete. Therefore, the
area analyzed was that around the negative area of the
implant. To facilitate comparisons, scores were converted
into percentile averages frequencies of 0%, 20% (10% to
30%), 60% (50% to 70%), and 90% (∗0% to 100%).International Journal of Dentistry 3
The results obtained considering the expression of RANK
in osteoblasts (GI) and RANK in osteoclasts (GII) were
joined, tabulated for analysis, and submitted to the Mann-
Whitney test to compare each group with each period,
and to the Kruskal-Wallis and Dunn Multiple Comparison
nonparametric tests (α = 5%) to compare each group in all
periods. The cells stained by immunohistochemistry, which
were shown to be multinucleated were considered to be
osteoclasts, and those around or within the bone trabeculae
that were not multinucleated, were considered osteoblasts.
3. Results
3.1. Clinical Analysis. None of the implants failed. All the
implants were stable, without loss of the surrounding bone.
Qualitative Imunohistochemistry Analysis. For imunohisto-
chemistry analysis, the imunolabelings taken into consider-
ation were those observed in the osteoclasts, osteoblasts, and
osteocytes in neoformed bone, around the implant (negative
area).
At 7 postoperative days, neoformed trabecular bone
tissue was observed with osteoblasts located around it
synthesizing bone matrix. In addition, connective tissue
was observed in some areas close to the implant. RANK
protein expression was observed in osteoblast lineage cells
(Figure 2(a)).
At 14 postoperative days, a larger quantity of bone for-
mation was observed. RANK immunolabeling was observed
in osteocyte phenotypes and bone-lining cells. There was
no expression in osteoblast phenotype cells in this period
(Figure 2(b)). At 21 postoperative days, RANK expression
was reduced when compared with previous periods and the
morphology of the cells diﬀered from the aspect observed
at 7 postoperative days (Figure 2(c)). Dispersed trabecular
bone was also observed, some cells with an aspect of
bone-lining cells or latent osteocytes, with no metabolic
activity. In some areas, it was possible to observe RANK
immunolabeling in macrophages or preosteoclasts. At 42
postoperative days, matured bone trabeculae were observed
(Figure). RANK expression was not present (Figure 2(d)).
3.2. Controls. The negative and positive controls, showed
the speciﬁcity of the reactions applied. The positive controls
were performed in slices from the rat nasal cavities, an area
in which RANK expression is observed in macrophages,
showing the speciﬁcity of the antibody used in the immuno-
labeling of preosteoclast lineage cells.
In addition, to evaluate the possibility of RANK protein
expression in osteoblast-lineage cells, immunohistochemical
reactions were performed in the rat embryo at 21 days of
pregnancy. A bodily structure that expresses only osteoblast-
lineage cells in primary bone tissue is the palatine pro-
cess. This process was also analyzed as a positive control
and showed positive immunolabeling for RANK protein
(Figure 3). The immunomarkings shown in Image 3 refer
to the RANK immunomarkings in areas outside of the
studied area, functioning as positive control to show the
eﬀectiveness of the antibody used. Figure 3(a) shows the
RANK expression in osteoclasts of the nasal mucosa of rats,
andFigure 3(b)showstheRANKexpressioninosteoblastsin
the primary bone tissue of rat embryos. These two regions
outside of the studied area are regions that are known to
have a large quantity of osteoclasts in the nasal cavity and
a large quantity of osteoblasts in rat embryos. Therefore, the
speciﬁcity of the antibody used is conﬁrmed.
Quantitative Imunohistochemistry Analysis. Figure 4 shows
the mean values (M) and the standard deviation (SD) for GI
and GII during diﬀerent periods analysed.
Statistically signiﬁcant diﬀerence was observed between
GI and GII at 7 and 14 postoperative days (P = .0109;
and .0420, resp.). Signiﬁcant diﬀerence was also observed
b e t w e e nG Ia t7a n dG Ia t1 4d a y s( P = .0012) (Figure 4).
4. Discussion
Several aspects must be considered in the results observed.
Immunohistochemistry is a methodological approach that
was recently introduced in the study of the bone-repair
process [20]. Since then, it has been used consistently, as
it allows the proteins present in cells to be identiﬁed, thus
contributing to a better understanding of bone biology.
The use of frozen sections was chosen, as this type of
procedure allows a greater preservation of tissue antigenicity,
giving better results of the labels observed. Therefore, it
must be considered that positive and negative controls
were performed with the aim of evaluating the absence of
unspeciﬁc labels, as well as speciﬁcity of labels in the primary
antibody used.
The interface formed between bone and implant has
been most studied and discussed by many research centers.
Considering that human bone tissue undergoes complete
reconstitution of the previous stage of injury, Walter and
Talbot [21] used the expression regeneration, instead of
repair process. Moreover, the regeneration process at the
interface occurs in the following three steps: hemostasis,
granulation tissue formation, and bone formation [22, 23].
The primary function of the interface formed between
the bone and implant is to provide a safe and eﬃcient charge
transfer through the implant to the bone tissue [24]. Many
studies have determined the factors that interfere in this
interface, among them, the type of surface, showing that
the diﬀerent surface treatments have positive eﬀects on the
initial bone repair in animals [25–28] and in humans [29].
Therefore, the purpose of this study was to evaluate the
machined surface implants, since the primary aim was to
evaluate the cellular responses during the osseointegration
process, considering RANK expression and not to compare
the topographical modiﬁcations of implant surfaces.
The results showed that RANK protein was expressed
in diﬀerent ways during the analyzed periods. The manner
that it was expressed was related to the dynamics of the
bone remodeling process. Studies have shown that RANK is
areceptorproteinexpressedinmacrophagesoftheosteoclast





Figure 1: Hematoxylin and eosin staining as a reference of the cytoarchiteture of the tissue. ((a) 63x; (b) 160x). Bone tissue formed around
the implant at 21 days postoperative.
(a) (b)
(c) (d)
Figure 2: RANK immunolabeling during bone-implant interface healing process during 7 (a), 14 (b), 21 (c), and 42 (d) days postoperative.
(a) (b)
Figure 3: Positive controls from RANK expression. (a) Rats nasal cavity showing RANK expression in preosteoclasts lineage cells. (b) Rat
embryo with 21 days of pregnancy. A bodily structure that expresses just osteoblasts lineage cells in primary bone tissue is the palatine























Figure 4: Comparison among RANK percentile values for each
group. GI: RANK immunolabeling in osteoblasts lineage cells; GII:
RANK immunolabeling in osteoclasts lineage cells.
analyzed results, it was observed that, particularly in the
21 postoperative days, there were some cells with an aspect
similar to that of osteoclastic macrophages presented RANK
protein immunolabeling, as described in literature [14, 30,
31]. Furthermore, at 7 days after implant placement, RANK
protein immunolabeling was observed in cells with a similar
morphology to that of osteoblasts and was located around
neoformed bone tissue. It was also observed in some areas,
the immunolabeling of cells similar to osteocytes, locked
into bone tissue lacunae was also observed. The RANK
immunolabeling cells with the aspect of osteoblasts, which
presented intense activity, were observed in all animals at 7
postoperative days.
A hypothesis that could explain the expression of RANK
protein in cells similar to osteoblasts would be that this
receptor protein is present in this type of cell, but it is
located in a less exposed manner that makes it diﬃcult
to label. Thus, when there is a stimulus such as in the
osseointegration process that evokes tissue preparation to
form bone around the inserted implant, this receptor could
change its conformation, becoming more exposed in the cell
membrane, and therefore positive to immunolabeling.
The presence of RANK in cells with osteoblast fenotypes
couldbejustiﬁedbasedonthehypothesisthatosteoblastsare
cells that present autocrine regulation, or that have receptors
of their secretion products. Since the osteoblasts synthesize,
it is possible that they must have the receptor of this ligand
or RANK protein. Pettit et al. [32] during the evaluation
of articular bone erosion in rheumatoid arthritis observed
RANK expression in cells that had morphological features of
osteoblasts. Furthermore, It must be considered that in our
positive control experiments, the RANK immunolabeling
was observed in primary bone of the palatine process of
an embryo at the end of pregnancy, showing that the
RANK protein or the RANK ligand receptor is present in
osteoblasts.
With regard to the temporal analysis of the osseointegra-
tion process, it was observed that after 14 postoperative days,
there was a decrease in the expression of RANK proteins in
osteoblasts lineage cells, and at 14 and 21 postoperative days,
it was observed the RANK immunolabeling in osteocytes
and bone-lining cell. At 42 days postoperative, there was no
expression of RANK protein in the bone tissue.
The immunohistochemistry approach could raise doubts
with regard to the observed results. Therefore, the control
reactions conﬁrmed the observed labelings.
Similar results were observed in our laboratory (paper
submitted for publication) when RANK expression in
osteoblasts during the alveolar healing process in rats. Coin-
cidentally, the larger RANK protein expression in osteoblasts
was at 14 days postoperative, a period market by greater
metabolic activity of the cells during the bone healing
process.
The results presented herein showed that osteoblast-
lineage cells express RANK protein in primary bone during
the initial periods of the bone-healing process around
titanium implants.
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